MBX Biosciences MBX
$49.55 −$3.86 (-7.23%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $49.55 0.00%
Open$53.48
Prev close$53.41
Day range$49.36 – $54.43
Volume581.9K
Market cap$2.46B
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$0.00
Operating profit-$66.34M-177.3% YoY
Net profit-$62.42M-188.7% YoY
Diluted EPS-$1.29-104.8% YoY
Free cash flow-$36.07M-64.4% YoY
Operating cash flow-$34.88M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Return on equity-33.7%
Return on assets-32.2%
Return on invested capital-37.1%
Current ratio19.58
Liabilities / assets5.5%
Cash & investments$481.59M
Total debt$2.50M
Net cash (debt)$479.09M
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Operating Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Expense | $66.34M | $40.93M | $27.27M | $98.06M | $25.80M |
| Selling and Admin Expenses | $34.30M | $9.95M | $8.79M | $18.90M | $6.04M |
| -General & Admin Expense | $34.30M | $9.95M | $8.79M | $18.90M | $6.04M |
| Research & Development | $32.05M | $30.99M | $18.47M | $79.16M | $19.76M |
| Operating Profit | -$66.34M | -$40.93M | -$27.27M | -$98.06M | -$25.80M |
| Net Non-Operating Interest Income (Expense) | $3.92M | $3.84M | $3.75M | $11.08M | $3.73M |
| Non-Operating Interest Income | $3.92M | $3.84M | $3.75M | $11.08M | $3.73M |
| Pretax Profit | -$62.42M | -$37.10M | -$23.52M | -$86.97M | -$22.06M |
| Net Profit | -$62.42M | -$37.10M | -$23.52M | -$86.97M | -$22.06M |
| Profit from Continuing Operations | -$62.42M | -$37.10M | -$23.52M | -$86.97M | -$22.06M |
| Net Income to Parent Company | -$62.42M | -$37.10M | -$23.52M | -$86.97M | -$22.06M |
| Net Income to Common Stockholders | -$62.42M | -$37.10M | -$23.52M | -$86.97M | -$22.06M |
| Basic EPS | -$1.29 | -$0.78 | -$0.50 | -$2.38 | -$0.49 |
| Diluted EPS | -$1.29 | -$0.78 | -$0.50 | -$2.38 | -$0.49 |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $500.62M | $435.91M | $452.70M | $385.14M | $385.14M |
| Total Current Assets | $492.76M | $427.86M | $448.54M | $381.54M | $381.54M |
| Cash and Cash Equivalents & Short-Term Investments | $481.59M | $418.58M | $439.98M | $373.71M | $373.71M |
| -Cash and Cash Equivalents | $161.69M | $54.12M | $45.21M | $75.29M | $75.29M |
| -Short Term Investments | $319.90M | $364.46M | $394.76M | $298.42M | $298.42M |
| Receivables | $3.23M | $3.04M | $3.16M | $2.12M | $2.12M |
| -Accrued Interest Receivable | $3.23M | $3.04M | $3.16M | $2.12M | $2.12M |
| Prepaid Assets | $5.45M | $5.07M | $4.59M | $4.85M | $4.85M |
| Other Current Assets | $2.48M | $1.16M | $814,000.00 | $861,000.00 | $861,000.00 |
| Total Non-Current Assets | $7.86M | $8.05M | $4.17M | $3.61M | $3.61M |
| Net PPE | $7.61M | $7.42M | $3.59M | $3.22M | $3.22M |
| -Gross PPE | $8.56M | $8.24M | $4.32M | $3.89M | $3.89M |
| -Accumulated Depreciation | -$952,000.00 | -$813,000.00 | -$734,000.00 | -$670,000.00 | -$670,000.00 |
| Non-Current Prepaid Assets | $42,000.00 | $42,000.00 | $42,000.00 | $42,000.00 | $42,000.00 |
| Non-Current Deferred Assets | $0.00 | $378,000.00 | $332,000.00 | $341,000.00 | $341,000.00 |
| Other Non-Current Assets | $205,000.00 | $205,000.00 | $205,000.00 | – | – |
| Total Liabilities | $27.67M | $26.37M | $14.95M | $15.92M | $15.92M |
| Total Current Liabilities | $25.17M | $23.66M | $14.57M | $15.50M | $15.50M |
| Payables | $6.81M | $4.36M | $6.97M | $2.98M | $2.98M |
| -Accounts Payable | $6.81M | $4.36M | $6.97M | $2.98M | $2.98M |
| Current Accrued Expenses | $11.99M | $14.06M | $5.08M | $8.03M | $8.03M |
| Short-Term Debt and Capital Lease Obligation | $787,000.00 | $631,000.00 | $178,000.00 | $172,000.00 | $172,000.00 |
| -Current Capital Lease Obligation | $787,000.00 | $631,000.00 | $178,000.00 | $172,000.00 | $172,000.00 |
| Total Non-Current Liabilities | $2.50M | $2.71M | $378,000.00 | $426,000.00 | $426,000.00 |
| Long Term Debt and Capital Lease Obligation | $2.50M | $2.71M | $377,000.00 | $424,000.00 | $424,000.00 |
| -Long Term Capital Lease Obligation | $2.50M | $2.71M | $377,000.00 | $424,000.00 | $424,000.00 |
| Total Equity | $472.95M | $409.54M | $437.76M | $369.22M | $369.22M |
| Stockholders' Equity | $472.95M | $409.54M | $437.76M | $369.22M | $369.22M |
| Capital Stock | $6,000.00 | $6,000.00 | $6,000.00 | $6,000.00 | $6,000.00 |
| -Common Stock | $6,000.00 | $6,000.00 | $6,000.00 | $6,000.00 | $6,000.00 |
| -Preferred Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Additional Paid-In Capital | $822.41M | $695.84M | $686.35M | $593.41M | $593.41M |
| Retained Earnings | -$347.51M | -$285.09M | -$247.99M | -$224.48M | -$224.48M |
| Gains/Losses Not Affecting Retained Earnings | -$1.96M | -$1.22M | -$606,000.00 | $286,000.00 | $286,000.00 |
| Other Non-Current Liabilities | – | – | $1,000.00 | $2,000.00 | $2,000.00 |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$34.88M | -$22.62M | -$20.21M | -$79.95M | -$18.30M |
| Net cash flow from continuing operations | -$34.88M | -$22.62M | -$20.21M | -$79.95M | -$18.30M |
| Net Income from Continuing Operations | -$62.42M | -$37.10M | -$23.52M | -$86.97M | -$22.06M |
| Depreciation & Depletion & Amortization | $140,000.00 | $79,000.00 | $64,000.00 | $248,000.00 | $60,000.00 |
| Other Non-Cash Items | $149,000.00 | $120,000.00 | $34,000.00 | $133,000.00 | $32,000.00 |
| Change in Working Capital | -$84,000.00 | $8.63M | -$1.69M | $1.58M | $1.57M |
| -Change in Prepaid Assets | -$2.10M | $258,000.00 | -$725,000.00 | -$2.70M | -$2.01M |
| -Change in Payables and Accrued Expense | $2.07M | $7.97M | -$885,000.00 | $4.34M | $3.59M |
| -Change in Other Current Assets | $0.00 | -$2.38M | -$43,000.00 | -$493,000.00 | $8,000.00 |
| -Change in Other Current Liabilities | -$49,000.00 | $2.79M | -$41,000.00 | $425,000.00 | -$27,000.00 |
| Net cash flow from investing | $42.83M | $29.21M | -$97.10M | -$83.71M | -$129.97M |
| Net Cash Flow from Continuing Investing Activities | $42.83M | $29.21M | -$97.10M | -$83.71M | -$129.97M |
| Net PPE Purchase and Sale | -$1.19M | -$901,000.00 | -$437,000.00 | -$1.93M | -$793,000.00 |
| Net Investment Purchase and Sale | $44.02M | $30.11M | -$96.66M | -$81.78M | -$129.18M |
| Financing Cash Flow | $99.61M | $2.32M | $87.44M | $189.59M | $438,000.00 |
| Net Cash Flow from Continuing Financing Activities | $99.61M | $2.32M | $87.44M | $189.59M | $438,000.00 |
| Net Common Stock Issuance | $97.24M | $254,000.00 | $85.37M | $187.95M | $0.00 |
| Proceeds from Stock Option Exercised | $2.41M | $2.19M | $2.44M | $2.42M | $955,000.00 |
| Net Other Financing Charges | -$31,000.00 | -$127,000.00 | -$378,000.00 | -$771,000.00 | -$517,000.00 |
| Ending Cash Balance | $161.90M | $54.33M | $45.42M | $75.29M | $75.29M |
| Net Change in Cash | $107.57M | $8.91M | -$29.87M | $25.94M | -$147.84M |
| Beginning Cash Balance | $54.33M | $45.42M | $75.29M | $49.35M | $223.13M |
| Free Cash Flow | -$36.07M | -$23.52M | -$20.65M | -$81.88M | -$19.09M |
| Net Preferred Stock Issuance | – | – | – | $0.00 | $0.00 |
No comments yet — be the first to weigh in on MBX.
Sign in to join the discussion.